Domov › Burkittov limfom › Kalifornija › Orange

Klinične študije za Burkittov limfom v Orange, CA

9 študij za Burkittov limfom išče udeležence na lokacijah v Orange in okolici (v razdalji približno 30 milj). Odprite študijo, da vidite, kdo lahko sodeluje in kako kontaktirati ekipo.

Uradno besedilo študije (angleško)

Iščete udeležence za študijo? Predstavite jo na vrhu te strani — $99 za 30 dni →

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

Vključevanje udeležencevFaza 2

Children's Hospital of Orange County, Orange

366 Days – 46 Years · Vsi spoli · Posodobljeno 2. okt. 2026 · NCT06124157

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

Vključevanje udeležencevFaza 3

UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange

Starost 18–39 · Vsi spoli · Posodobljeno 2. okt. 2026 · NCT03150693

Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

Vključevanje udeležencevFaza 2

UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange

Starost 18 in več · Vsi spoli · Posodobljeno 29. sep. 2026 · NCT03739814

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

Vključevanje udeležencevFaza 2

Children's Hospital of Orange County, Orange

365 Days · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT06317662

Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

Vključevanje udeležencevFaza 3

UC Irvine, Orange

Starost 18 in več · Vsi spoli · Posodobljeno 21. sep. 2026 · NCT07648264

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Vključevanje udeležencevFaza 2

Children's Hospital of Orange County, Orange

Starost 1–30 · Vsi spoli · Posodobljeno 1. sep. 2026 · NCT04546399

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

Vključevanje udeležencevFaza 3

Children's Hospital of Orange County, Orange

365 Days – 25 Years · Vsi spoli · Posodobljeno 25. avg. 2026 · NCT03959085

Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL

Vključevanje udeležencevFaza 2

Children's Hospital Orange County, Orange

Starost 7–25 · Vsi spoli · Posodobljeno 19. avg. 2026 · NCT05082519

Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene

Vključevanje udeležencevFaza 1/2

UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange

Starost 18 in več · Vsi spoli · Posodobljeno 31. jul. 2026 · NCT07069699

Študije za Burkittov limfom v drugih mestih

Druge študije v Orange

Vir: ClinicalTrials.gov, podatki pridobljeni 6. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.